Recent 8-K filings for AURX
Highest-materiality recent filing
Nuo Therapeutics closes $325,000 Second Funding, reaching $2,000,000 total loan funding
- Nuo Therapeutics received the $325,000 Second Funding on October 6, 2026, bringing aggregate Lender funding under the Loan Agreement to $2,000,000.
- The Second Closing Date was moved from September 30 to October 6, 2026 via an Assignment, Joinder, and Amendment No. 1.
-
Nuo Therapeutics closes $325,000 Second Funding, reaching $2,000,000 total loan funding
Nuo Therapeutics received the $325,000 Second Funding on October 6, 2026, bringing aggregate Lender funding under the Loan Agreement to $2,000,000.
-
Nuo Therapeutics Q2 2026 revenue up >150% YoY; operating loss narrows to $167K
Q2 2026 total revenues ~$1.77M, up >150% YoY; H1 2026 revenues ~$3.07M, also up >150%.
-
Nuo Therapeutics secures $2M loan facility; issues warrants at $1.50 strike
Amended loan agreement increases aggregate commitment by $400k to $2.0M; $675k funded on May 29, 2026.
-
Nuo Therapeutics Q1 revenues up 169% YoY to $1.3M; operating loss narrows
Total revenue $1.3M, including $1.22M product sales, up 169% YoY and 20% sequential.
-
Loan agreement for $1.0M initial + $600K second tranche (Sept 30, 2026); $1.0M funded Jan 23, 2026.
-
Nuo Therapeutics shareholders elect four directors and ratify auditor at 2025 annual meeting
All four director nominees elected: David E. Jorden, Paul D. Mintz, Scott M. Pittman, C. Eric Winzer.
-
Nuo Therapeutics raises CEO and COO salaries, sets Dec 16 annual meeting
CEO David E. Jorden salary increased to $325,000 effective Oct 1, 2025.
-
Nuo Therapeutics enters interim sales agency agreement with Smith+Nephew for Aurix products
Amendment to Distribution Agreement grants Smith+Nephew interim sales agent role for Nuo Aurix brand to certain Smith+Nephew customers.
-
Nuo Therapeutics raises $849k in private placement of 1.13M shares at $0.75/share
Gross proceeds of $849,125 from sale of 1,132,167 shares at $0.75 per share.
-
Pacific Medical exercises full warrant for 356,889 shares of Nuo Therapeutics common stock
Pacific Medical exercised warrant for 270,000 shares at $0.56/share, raising $151,200 in cash proceeds.
-
Nuo Therapeutics dismisses auditor Marcum, engages MaloneBailey; cites material weaknesses
Effective June 7, 2024, dismissed Marcum LLP as independent auditor; engaged MaloneBailey, LLP for FY 2024.
-
Nuo Therapeutics raises $650,875 in private placement of 867,833 shares at $0.75/share
Gross proceeds of $650,875 from sale of 867,833 shares of common stock at $0.75 per share.
-
Nuo Therapeutics delays annual 10-K filing to April 19 for audit finalization
Company will not file Form 10-K by April 16 as previously expected.
-
Nuo Therapeutics raises $962,500 in private placement of 1.925M shares at $0.50/share
Sold 1,925,000 common shares at $0.50 each for gross proceeds of $962,500.
-
Nuo Therapeutics raises $1.035M in private placement at $2.00/share; insiders participate
Gross proceeds of $1,035,000 from sale of 517,500 shares of common stock at $2.00 per share.
-
Nuo Therapeutics shareholders approve all proposals at 2022 annual meeting
Re-elected David E. Jorden, C. Eric Winzer, Scott M. Pittman, and Paul D. Mintz as directors.
-
Nuo Therapeutics sets 2022 Annual Meeting for Dec 2; record date Sept 30
Annual Meeting will be held at 8285 El Rio, Suite 190, Houston, Texas on December 2, 2022.
-
Nuo Therapeutics secures $500K equity investment from distributor Pacific Medical; raises $4.5M YTD
PacMed invests $500K for 500K shares at $1.00; receives two warrants for up to 450K shares tied to sales quotas.
-
Nuo Therapeutics enters exclusive distribution agreement with Pacific Medical for Aurix System
Appointed Pacific Medical as exclusive distributor for Aurix System in six+ western states (WA, OR, ID, MT, WY, most CA, northern NV, AK).
-
Nuo Therapeutics raises $3.55M in private placement at $1.00/share with insider participation
Sold 3,550,000 shares of common stock at $1.00 per share for gross proceeds of $3,550,000.
-
Nuo Therapeutics modifies warrant exercise price; all warrants exercised for 6.87M shares and $1.37M
Warrant exercise price reduced from $0.40 to $0.20 per share, with exercise required by Jan 31, 2022.
Materiality & sentiment trend
Max materiality 0.75 · Median 0.50 · Most common event other_material